Atherosclerosis
Volume 196, Issue 2 , Pages 558-564 , February 2008

Lysyl oxidase (LOX) down-regulation by TNFα: A new mechanism underlying TNFα-induced endothelial dysfunction

Received 1 March 2007 ,Revised 6 June 2007 ,Accepted 15 June 2007.

References 

  1. Mehta JL, Li DY. Inflammation in ischemic heart disease: response to tissue injury or a pathogenetic villain?. Cardiovasc Res. 1999;43:291–299
  2. Ross R. Atherosclerosis—an inflammatory disease. N Engl J Med. 1999;340:115–126
  3. Fiichtlscherer S, Rossig L, Breuer S, Vasa M, Dimmeler S, Zeiher AM. Tumor necrosis factor antagonism with etanercept improves systemic endothelial vasoreactivity in patients with advanced heart failure. Circulation. 2001;104:3023–3025
  4. Agnoletti L, Curello S, Bachetti T, et al. Serum from patients with severe heart failure down-regulates eNOS and is proapoptotic: role of tumor necrosis factor-alpha. Circulation. 1999;100:1983–1991
  5. Wang P, Ba ZF, Chaudry IH. Administration of tumor necrosis factor-alpha in vivo depresses endothelium-dependent relaxation. Am J Physiol. 1994;266:H2535–H2541
  6. Ferro T, Neumann P, Gertzberg N, Clements R, Johnson A. Protein kinase C-alpha mediates endothelial barrier dysfunction induced by TNF-alpha. Am J Physiol Lung Cell Mol Physiol. 2000;278:L1107–L1117
  7. Krasinski K, Spyridopoulos I, Kearney M, Losordo DW. In vivo blockade of tumor necrosis factor-alpha accelerates functional endothelial recovery after balloon angioplasty. Circulation. 2001;104:1754–1756
  8. Picchi A, Gao X, Belmadani S, et al. Tumor necrosis factor-alpha induces endothelial dysfunction in the prediabetic metabolic syndrome. Circ Res. 2006;99:69–77
  9. Nystrom T, Nygren A, Sjoholm A. Increased levels of tumour necrosis factor-alpha (TNF-alpha) in patients with Type II diabetes mellitus after myocardial infarction are related to endothelial dysfunction. Clin Sci (Lond). 2006;110:673–681
  10. Mann DL. Targeted anticytokine therapy and the failing heart. Am J Cardiol. 2005;95:9C–16C
  11. Kagan HM, Li W. Lysyl oxidase: properties, specificity, and biological roles inside and outside of the cell. J Cell Biochem. 2003;88:660–672
  12. Erler JT, Bennewith KL, Nicolau M, et al. Lysyl oxidase is essential for hypoxia-induced metastasis. Nature. 2006;440:1222–1226
  13. Song YL, Ford JW, Gordon D, Shanley CJ. Regulation of lysyl oxidase by interferon-γ in rat aortic smooth muscle cells. Arterioscler Thromb Vasc Biol. 2000;20:982–988
  14. Maki JM, Rasanen J, Tikkanen H, et al. Inactivation of the lysyl oxidase gene Lox leads to aortic aneurysms, cardiovascular dysfunction and perinatal death in mice. Circulation. 2002;106:2503–2509
  15. Rodríguez C, Raposo B, Martínez-González J, Casani L, Badimon L. Low density lipoproteins down-regulates lysyl oxidase in vascular endothelial cells and the arterial wall. Arterioscler Thromb Vasc Biol. 2002;22:1409–1414
  16. Raposo B, Rodríguez C, Martínez-González J, Badimon L. High levels of homocysteine inhibit lysyl oxidase (LOX) and down-regulates LOX expression in vascular endothelial cells. Atherosclerosis. 2004;177:1–8
  17. Rodríguez C, Martínez-González J, Sánchez-Gómez S, Badimon L. LDL down-regulates CYP51 in porcine vascular endothelial cells and in the arterial wall through a sterol regulatory element binding protein-2-dependent mechanism. Circ Res. 2001;88:268–274
  18. Rodríguez C, Raposo B, Martínez-González J, Llorente-Cortes V, Vilahur G, Badimon L. Modulation of ERG25 expression by LDL in vascular cells. Cardiovasc Res. 2003;58:178–185
  19. Martínez-González J, Raposo B, Rodríguez C, Badimon L. 3-Hydroxy-3-methylglutaryl coenzyme a reductase inhibition prevents endothelial NO synthase down-regulation by atherogenic levels of native LDLs: balance between transcriptional and posttranscriptional regulation. Arterioscler Thromb Vasc Biol. 2001;21:804–809
  20. García-Ramírez M, Martínez-González J, Juan-Babot JO, Rodríguez C, Badimon L. Transcription factor SOX18 is expressed in human coronary atherosclerotic lesions and regulates DNA synthesis and vascular cell growth. Arterioscler Thromb Vasc Biol. 2005;25:2398–2403
  21. Masaki T, Yoshimatsu H, Kakuma T, et al. Induction of rat uncoupling protein-2 gene treated with tumour necrosis factor alpha in vivo. Eur J Clin Invest. 1999;29:76–82
  22. Hornstra IK, Birge S, Starcher B, Bailey AJ, Mecham RP, Shapiro SD. Lysyl oxidase is required for vascular and diaphragmatic development in mice. J Biol Chem. 2003;278:14387–14393
  23. Huffman MD, Curci JA, Moore G, Kerns DB, Starcher BC, Thompson RW. Functional importance of connective tissue repair during the development of experimental abdominal aortic aneurysms. Surgery. 2000;128:429–438
  24. Sullivan CJ, Teal TH, Luttrell IP, Tran KB, Peters MA, Wessells H. Microarray analysis reveals novel gene expression changes associated with erectile dysfunction in diabetic rats. Physiol Genomics. 2005;23:192–205
  25. Pischon N, Darbois LM, Palamakumbura AH, Kessler E, Trackman PC. Regulation of collagen deposition and lysyl oxidase by tumor necrosis factor-alpha in osteoblasts. J Biol Chem. 2004;279:30060–30065
  26. Kishore R, Luedemann C, Bord E, Goukassian D, Losordo DW. Tumor necrosis factor-mediated E2F1 suppression in endothelial cells: differential requirement of c-Jun N-terminal kinase and p38 mitogen-activated protein kinase signal transduction pathways. Circ Res. 2003;93:932–940
  27. Kishore R, Qin G, Luedemann C, et al. The cytoskeletal protein ezrin regulates EC proliferation and angiogenesis via TNF-alpha-induced transcriptional repression of cyclin A. J Clin Invest. 2005;115:1785–1796
  28. Min W, Pober JS. TNF initiates E-selectin transcription in human endothelial cells through parallel TRAF-NF-kappa B and TRAF-RAC/CDC42-JNK-c-Jun/ATF2 pathways. J Immunol. 1997;159:3508–3518
  29. Pohlman TH, Harlan JM. Human endothelial cell response to lipopolysaccharide, interleukin-1, and tumor necrosis factor is regulated by protein synthesis. Cell Immunol. 1989;119:41–52
  30. MacEwan DJ. TNF receptor subtype signalling: differences and cellular consequences. Cell Signal. 2002;14:477–492
  31. Corredor J, Yan F, Shen CC, et al. Tumor necrosis factor regulates intestinal epithelial cell migration by receptor-dependent mechanisms. Am J Physiol Cell Physiol. 2003;284:C953–C961
  32. Pan S, An P, Zhang R, He X, Yin G, Min W. Etk/Bmx as a tumor necrosis factor receptor type 2-specific kinase: role in endothelial cell migration and angiogenesis. Mol Cell Biol. 2002;22:7512–7523
  33. Grech AP, Gardam S, Chan T, et al. Tumor necrosis factor receptor 2 (TNFR2) signaling is negatively regulated by a novel, carboxyl-terminal TNFR-associated factor 2 (TRAF2)-binding site. J Biol Chem. 2005;280:31572–31581

PII: S0021-9150(07)00384-X

doi: 10.1016/j.atherosclerosis.2007.06.002

Atherosclerosis
Volume 196, Issue 2 , Pages 558-564 , February 2008

Article Tools

* Image Usage & Resolution